Meeting
2021 Genitourinary Cancers Symposium
A phase I study of capivasertib in combination with abiraterone acetate in patients with metastatic castration-resistant prostate cancer.
Authors
Neal D. Shore
Carolina Urologic Research Center, Myrtle Beach, SC
Neal D. Shore , Begona Mellado , Satish Shah , Ralph J. Hauke , Dan Costin , Thomas Morris , Rana Anjum , Zsolt Szijgyarto , Remy B Verheijen , Marie Cullberg
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session: Prostate Cancer - Advanced Disease
Track
Prostate Cancer - Advanced
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT04087174
Citation
J Clin Oncol 39, 2021 (suppl 6; abstr 85)
DOI
10.1200/JCO.2021.39.6_suppl.85
Abstract #
85
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Genitourinary Cancers Symposium
First-in-human phase 1 study of CC-94676, a first-in-class androgen receptor (AR) ligand-directed degrader (LDD), in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
First Author: Dana E. Rathkopf
Poster
2023 ASCO Genitourinary Cancers Symposium
CAPItello-280: A phase III study of capivasertib and docetaxel versus placebo and docetaxel in metastatic castration-resistant prostate cancer.
First Author: Simon J. Crabb
Poster
2022 ASCO Genitourinary Cancers Symposium
Phase 1 results of the ODM-208 first-in-human phase 1-2 trial in patients with metastatic castration-resistant prostate cancer (CYPIDES).
First Author: Karim Fizazi
First Author: Johann S. De Bono